9999999997-19-003511.txt : 20190426 9999999997-19-003511.hdr.sgml : 20190426 20190426141621 ACCESSION NUMBER: 9999999997-19-003511 CONFORMED SUBMISSION TYPE: CT ORDER PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20190426 DATE AS OF CHANGE: 20190426 ACTION DATE: 20190426 RECEIVED DATE: 20190426 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Orexigen Therapeutics, Inc. CENTRAL INDEX KEY: 0001382911 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 651178822 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: CT ORDER SEC ACT: 1934 Act SEC FILE NUMBER: 001-33415 FILM NUMBER: 19770965 BUSINESS ADDRESS: STREET 1: 3344 N. TORREY PINES CT. STREET 2: SUITE 200 CITY: LA JOLLA STATE: CA ZIP: 92037 BUSINESS PHONE: (858) 875-8600 MAIL ADDRESS: STREET 1: 3344 N. TORREY PINES CT. STREET 2: SUITE 200 CITY: LA JOLLA STATE: CA ZIP: 92037 CT ORDER 1 filename1.pdf begin 644 filename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